More health insurance coverage for Synagis injection

Starting this month, the government has provided more coverage for Abbott’s Synagis inj. (palivizumab) to reduce respiratory syncytial virus (RSV) infections in infants.

The Ministry of Health and Welfare said Monday that the national health insurance further covers infants with a history of premature birth (less than 31 weeks gestational age) as well as children with hemodynamically signifi...